Rebamipide and Pantoprazole Combination in NSAIDs-Gastropathy Treatment

Abstract

The objective of this study was to investigate the pantoprazole and rebamipide efficiency on NSAIDs (nonsteroidal anti-inflammatory drugs)-gastropathy restoring and healing in patients with coronary heart disease, stable angina, who have been taking aspirin for a long time period. The study included three groups of patients according to the treatment they have got: ASA (acetylsalicylic acid) in the first group; ASA and pantoprazole in the second; ASA, pantoprazole and rebamipide in the third one. To obtain the results, endoscopic method and proinflammatory cytokines LTB4 and protective prostaglandin E2 determination in the blood were used. The research demonstrated no ulcer effects in the group of patients who were treated by rebamipide, and significantly fewer gastroduodenal erosions, in comparison to the group, where treatment contained ASA and pantoprazole. The LTB4 (leukotriene B4) level decreased in pantoprazole and rebamipide treatment groups, but the PGE2 (prostaglandin E2) level increased only after rebamipide therapy. Therefore, rebamipide should be included to the therapy for the better NSAIDs-gastropathy treatment, in reason of its good reparative and gastroprotective properties.